EA023238B1 - Замещенные производные индола для лечения иммунологических расстройств - Google Patents

Замещенные производные индола для лечения иммунологических расстройств Download PDF

Info

Publication number
EA023238B1
EA023238B1 EA201391710A EA201391710A EA023238B1 EA 023238 B1 EA023238 B1 EA 023238B1 EA 201391710 A EA201391710 A EA 201391710A EA 201391710 A EA201391710 A EA 201391710A EA 023238 B1 EA023238 B1 EA 023238B1
Authority
EA
Eurasian Patent Office
Prior art keywords
formula
alkyl
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
EA201391710A
Other languages
English (en)
Russian (ru)
Other versions
EA201391710A1 (ru
Inventor
Найджел Грэхэм Кук
Рита Рамос
Карен Каммертэн
Морис Ван Эйс
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201391710A1 publication Critical patent/EA201391710A1/ru
Publication of EA023238B1 publication Critical patent/EA023238B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
EA201391710A 2011-05-17 2012-05-16 Замещенные производные индола для лечения иммунологических расстройств EA023238B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161486808P 2011-05-17 2011-05-17
PCT/IB2012/052473 WO2012156936A1 (en) 2011-05-17 2012-05-16 Substituted indole derivatives for the treatment of immunological disorders

Publications (2)

Publication Number Publication Date
EA201391710A1 EA201391710A1 (ru) 2014-03-31
EA023238B1 true EA023238B1 (ru) 2016-05-31

Family

ID=46210333

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391710A EA023238B1 (ru) 2011-05-17 2012-05-16 Замещенные производные индола для лечения иммунологических расстройств

Country Status (15)

Country Link
US (2) US8703782B2 (https=)
EP (1) EP2709998B1 (https=)
JP (1) JP6043344B2 (https=)
KR (1) KR20140023354A (https=)
CN (1) CN103534250B (https=)
AR (1) AR088414A1 (https=)
AU (1) AU2012257345B2 (https=)
BR (1) BR112013029416A2 (https=)
CA (1) CA2835169C (https=)
EA (1) EA023238B1 (https=)
ES (1) ES2565200T3 (https=)
MX (1) MX2013013436A (https=)
TW (1) TW201249858A (https=)
UY (1) UY34072A (https=)
WO (1) WO2012156936A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34072A (es) 2011-05-17 2013-01-03 Novartis Ag Derivados sustituidos de indol
BR112015009214A2 (pt) * 2012-11-07 2017-07-04 Novartis Ag derivados de indol substituído
CN105828822B (zh) 2013-08-14 2019-10-18 诺华股份有限公司 用于治疗癌症的组合疗法
ES2851724T3 (es) 2013-09-18 2021-09-08 Epiaxis Therapeutics Pty Ltd Modulación de células madre
CA2958704A1 (en) 2014-08-25 2016-03-03 University Of Canberra Compositions for modulating cancer stem cells and uses therefor
WO2025091442A1 (zh) * 2023-11-03 2025-05-08 北京凯因科技股份有限公司 一种神经氨酸酶抑制剂及在流感病毒中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027106A1 (en) * 1999-10-12 2001-04-19 F. Hoffmann-La Roche Ag Substituted pyrroles as antiproliferative agents for the treatment of cancer
WO2003082859A1 (en) * 2002-04-03 2003-10-09 Novartis Ag Indolylmaleimide derivatives

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925860A (en) 1987-08-05 1990-05-15 E. I. Du Pont De Nemours And Company Stable pharmaceutical composition of 3-(hydroxymethyl)-5,5-diphenylhydantoin disodium phosphate ester
DE4005970A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
EP2070921A1 (en) 2000-11-07 2009-06-17 Novartis Ag Indolylmaleimide derivatives as protein kinase c inhibitors
JP4369237B2 (ja) 2001-12-21 2009-11-18 エーザイ コーポレーション オブ ノース アメリカ アルコールおよびフェノールの水溶性ホスホノオキシメチル誘導体の調製法
NZ533536A (en) 2001-12-28 2006-11-30 Mgi Gp Inc Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol such as O-phosphonooxymethyl propofol
HUP0600241A2 (en) 2002-04-08 2006-07-28 Mgi Gp Pharmaceutical compositions containing water-soluble prodrugs of propofol and methods of administering same
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
AU2003223104A1 (en) 2003-03-19 2004-10-11 Suven Life Sciences Limited A process for the preparation of indolymaleimides
AU2006206458B2 (en) 2005-01-19 2012-10-25 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
WO2007008514A2 (en) 2005-07-07 2007-01-18 Georgetown University Inhibitors of glycogen synthase kinase 3
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
GB0605691D0 (en) 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
ATE540041T1 (de) 2006-11-21 2012-01-15 Rigel Pharmaceuticals Inc Prodrug-salze von 2,4-pyrimidindiaminverbindungen und anwendungen davon
WO2011057204A2 (en) 2009-11-06 2011-05-12 The Johns Hopkins University Lrrk2-mediated neuronal toxicity
CN101812097B (zh) 2010-04-17 2012-04-25 中国海洋大学 吲哚咔唑和双吲哚马来酰亚胺生物碱及其制备方法和应用
UY34072A (es) 2011-05-17 2013-01-03 Novartis Ag Derivados sustituidos de indol

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027106A1 (en) * 1999-10-12 2001-04-19 F. Hoffmann-La Roche Ag Substituted pyrroles as antiproliferative agents for the treatment of cancer
WO2003082859A1 (en) * 2002-04-03 2003-10-09 Novartis Ag Indolylmaleimide derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KUMPULAINEN H. ET AL.: "Synthesis, in vitro and in vivo characterization of novel ethyl dioxy phosphate prodrug of propofol", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 34, no. 2-3, 3 July 2008 (2008-07-03), pages 110-117, XP022696122, ISSN: 0928-0987, DOI: 10.1016/J.EJPS.2008.02.121 [retrieved on 2008-03-02], page 110, left-hand column, last paragraph *

Also Published As

Publication number Publication date
WO2012156936A1 (en) 2012-11-22
TW201249858A (en) 2012-12-16
AR088414A1 (es) 2014-06-11
EA201391710A1 (ru) 2014-03-31
JP6043344B2 (ja) 2016-12-14
CN103534250A (zh) 2014-01-22
EP2709998B1 (en) 2016-01-06
CN103534250B (zh) 2016-05-11
MX2013013436A (es) 2013-12-06
EP2709998A1 (en) 2014-03-26
ES2565200T3 (es) 2016-04-01
UY34072A (es) 2013-01-03
JP2014518870A (ja) 2014-08-07
CA2835169C (en) 2019-05-14
US9029396B2 (en) 2015-05-12
AU2012257345B2 (en) 2016-03-24
BR112013029416A2 (pt) 2017-01-31
US20140179634A1 (en) 2014-06-26
US8703782B2 (en) 2014-04-22
KR20140023354A (ko) 2014-02-26
CA2835169A1 (en) 2012-11-22
US20130157980A1 (en) 2013-06-20

Similar Documents

Publication Publication Date Title
US12275726B2 (en) Aurora kinase inhibitors and use thereof
JP2022071072A (ja) （ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラ－ヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミドの結晶形、その調製、及びその使用
CN111315747B (zh) 二氢吡唑酮并嘧啶类化合物及其制备方法和用途
EP3728271A1 (en) Macrocyclic compounds for treating disease
CN113527299A (zh) 一类含氮稠环类化合物、制备方法和用途
JP2009544592A (ja) Ｊａｋキナーゼ阻害剤としての２，４−ジ（アリールアミノ）−ピリミジン−５−カルボキサミド化合物
CN113912648A (zh) 一种二氨基嘧啶化合物及包含该化合物的组合物
EA023238B1 (ru) Замещенные производные индола для лечения иммунологических расстройств
JP2019526605A (ja) 置換２−ｈ−ピラゾール誘導体の結晶形、塩型及びその製造方法
EP4069700A1 (en) Macrocycles for use in treating disease
AU2012257345A1 (en) Substituted indole derivatives for the treatment of immunological disorders
TW202136267A (zh) Ｂｒｕｔｏｎ酪胺酸激酶（ＢＴＫ）抑制劑
AU2020410900B2 (en) Compound used as RET kinase inhibitor and application thereof
EP3978492B1 (en) BICYCLIC COMPOUND AS A RIP-1 KINASE INHIBITOR AND ITS APPLICATION
JP2016500057A (ja) 置換インドール誘導体
TW202333713A (zh) 一種噠嗪類化合物、其藥物組合物及應用
WO2022268065A1 (en) Compounds as erk inhibitors
JP2023543080A (ja) ピロロ複素環系誘導体の結晶及びその製造方法
EP4269409A1 (en) Amide oxazole compound
TW202327593A (zh) Kras抑制劑的多晶型物及其製備方法和用途
CN104768945A (zh) 取代的吲哚衍生物
HK1164698A1 (en) Crystalline forms of genistein

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU